<![CDATA[INT230-6 Combination Resumes Dosing in Phase 2 Presurgical TNBC Trial]]>

Phase 2INT230-6Positive

AI Analysis

Summary

Dosing has resumed in the INVINCIBLE-4 Phase 2 presurgical trial evaluating INT230-6 in combination with standard therapy for early-stage triple-negative breast cancer.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Dosing resumed in INVINCIBLE-4 trial

Importance:4/10

Sentiment:

0.50

INT230-6triple-negative breast cancerINVINCIBLE-4presurgicalPhase 2

Related Companies

$INTS

Read the original article

Published by Cancer Network on July 16, 2026 3:00 PM

Read Original